Literature DB >> 16086536

Cost-utility of 2 maintenance treatments for older adults with depression who responded to a course of electroconvulsive therapy: results from a decision analytic model.

Mohamed Aziz1, Ann M Mehringer, Ellen Mozurkewich, Gihan N Razik.   

Abstract

OBJECTIVE: The prevalence of major depressive disorder (MDD) in community-dwelling elderly populations is 1% to 3%. After initial treatment of the acute phase of depression, only about 25% to 30% of elderly patients remain well after 1 to 3 years of follow-up. Previous studies suggested that patients who received maintenance electroconvulsive therapy (MECT) demonstrated lower relapse rates, a better subjective sense of well-being, and lower health care costs at 12-month follow-up. This study provides a cost-utility analysis of 2 maintenance treatments for recurrent depression in elderly patients.
METHOD: We used a Markov decision model to compare maintenance pharmacotherapy (MPT) with MECT in a theoretical cohort of elderly individuals with MDD who responded to an initial course of ECT. We estimated total costs and total quality-adjusted life years (QALYs) for each strategy as well as the cost per QALY.
RESULTS: The model produced a cost per patient of dollar 436,102 for MPT and dollar 281,356 for MECT. The MPT strategy yielded 7.55 QALYs and the MECT strategy yielded 11.43 QALYs. Therefore, MPT cost dollar 57,762 per QALY and MECT cost dollar 24,616 per QALY.
CONCLUSION: Our model suggests that MECT may be more cost-effective than MPT in the maintenance treatment of older adults with depression who have responded to a course of acute ETC.

Entities:  

Mesh:

Year:  2005        PMID: 16086536

Source DB:  PubMed          Journal:  Can J Psychiatry        ISSN: 0706-7437            Impact factor:   4.356


  10 in total

1.  A proposed model for economic evaluations of major depressive disorder.

Authors:  Hossein Haji Ali Afzali; Jonathan Karnon; Jodi Gray
Journal:  Eur J Health Econ       Date:  2011-06-02

2.  Cross-cultural evaluation of the French version of the LEIPAD, a health-related quality of life instrument for use in the elderly living at home.

Authors:  I Jalenques; C Auclair; J Roblin; D Morand; R Tourtauchaux; R May; E Vaille-Perret; J Watts; L Gerbaud; D De Leo
Journal:  Qual Life Res       Date:  2012-04-03       Impact factor: 4.147

Review 3.  Continuation and maintenance electroconvulsive therapy for mood disorders: review of the literature.

Authors:  Georgios Petrides; Kristen G Tobias; Charles H Kellner; Matthew V Rudorfer
Journal:  Neuropsychobiology       Date:  2011-07-29       Impact factor: 2.328

Review 4.  A critical review of model-based economic studies of depression: modelling techniques, model structure and data sources.

Authors:  Hossein Haji Ali Afzali; Jonathan Karnon; Jodi Gray
Journal:  Pharmacoeconomics       Date:  2012-06-01       Impact factor: 4.981

5.  Beyond symptomatic improvement:assessing real-world outcomes in patients with major depressive disorder.

Authors:  Alan M Langlieb; Christine J Guico-Pabia
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2010

Review 6.  The estimation of utility weights in cost-utility analysis for mental disorders: a systematic review.

Authors:  Michael Sonntag; Hans-Helmut König; Alexander Konnopka
Journal:  Pharmacoeconomics       Date:  2013-12       Impact factor: 4.981

7.  Methodologies used in cost-effectiveness models for evaluating treatments in major depressive disorder: a systematic review.

Authors:  Sorrel E Wolowacz; Peter M Classi; Julie Birt; Evelina A Zimovetz
Journal:  Cost Eff Resour Alloc       Date:  2012-02-01

8.  The Psychiatric Patient as a Health Resource Consumer: Costs Associated with Electroconvulsive Therapy.

Authors:  Carmen Selva-Sevilla; Maria Luisa Gonzalez-Moral; Maria Teresa Tolosa-Perez
Journal:  Front Psychol       Date:  2016-05-27

Review 9.  Model-Based Economic Evaluation of Treatments for Depression: A Systematic Literature Review.

Authors:  Spyros Kolovos; Judith E Bosmans; Heleen Riper; Karine Chevreul; Veerle M H Coupé; Maurits W van Tulder
Journal:  Pharmacoecon Open       Date:  2017-09

10.  Validation of the French version of the LEIPAD in community-dwelling people aged 80 years and above.

Authors:  Isabelle Jalenques; Candy Guiguet-Auclair; Laurent Gerbaud; Chloé Rachez; Fabien Rondepierre
Journal:  PLoS One       Date:  2019-03-19       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.